Literature DB >> 10626791

Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene.

T Minaguchi1, T Mori, Y Kanamori, M Matsushima, H Yoshikawa, Y Taketani, Y Nakamura.   

Abstract

A tumor suppressor gene on chromosome 10q23, PTEN, encodes a phosphatidylinositol phosphatase that antagonizes activation of the phosphatidylinositol 3'-kinase-mediated pathway involved in cell growth. A gene encoding the catalytic subunit of phosphatidylinositol 3'-kinase (PIK3CA) is frequently activated in ovarian cancers; therefore, overexpression of the PTEN product through gene transfer might be an effective strategy for treating ovarian cancers. To test the potential for this type of gene therapy, we constructed a recombinant adenovirus encoding wild-type PTEN and examined its effects on nine cell lines derived from human ovarian carcinomas. Transduction of the PTEN gene significantly inhibited growth of six of these cell lines compared with infection with virus alone, and the degree of inhibition correlated with the efficiency of gene transfer as determined by beta-galactosidase assay. Results of flow cytometry suggested that the observed effects were mediated by two mechanisms, apoptosis and/or arrest in the G1 phase of the cell cycle, and that high adenoviral transduction efficiency of cells was associated with induction of apoptosis. We also found that the level of transcription of Integrin alpha(v) in ovarian cancer cells correlated with the efficiency of transduction (P = 0.014) and with the degree of growth inhibition after PTEN gene transfer (P = 0.009). These findings carry significant implications for adenovirus vector-based PTEN gene therapies for ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene.

Authors:  Ying Hang; Yong-Chen Zheng; Yan Cao; Qing-Shan Li; Yu-Jie Sui
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

2.  Synergism between RIZ1 gene therapy and paclitaxel in SiHa cervical cancer cells.

Authors:  H Y Cheng; T Zhang; Y Qu; W J Shi; G Lou; Y X Liu; Y Y Zhang; L Cheng
Journal:  Cancer Gene Ther       Date:  2016-10-07       Impact factor: 5.987

3.  The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  Jing Cai; Linjuan Xu; Huijuan Tang; Qiang Yang; Xiaoqing Yi; Yan Fang; Ying Zhu; Zehua Wang
Journal:  Oncologist       Date:  2014-04-09

Review 4.  Cell Cycle Control by PTEN.

Authors:  Andrew Brandmaier; Sheng-Qi Hou; Wen H Shen
Journal:  J Mol Biol       Date:  2017-06-09       Impact factor: 5.469

Review 5.  Genetic factors in ovarian carcinoma.

Authors:  A J Li; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

6.  Exogenous PTEN gene induces apoptosis in breast carcinoma cell line MDA468.

Authors:  Qingyong Chen; Chunyou Wang; Chunfang Jiang; Daoda Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

7.  Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene.

Authors:  Miao Ding; Xin Cao; Hai-neng Xu; Jun-kai Fan; Hong-ling Huang; Dong-qin Yang; Yu-hua Li; Jian Wang; Runsheng Li; Xin-yuan Liu
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

8.  Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor.

Authors:  Ray-Chang Wu; Martina Blumenthal; Xinwei Li; Axel H Schönthal
Journal:  BMC Mol Biol       Date:  2002-07-12       Impact factor: 2.946

9.  Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas.

Authors:  A Akiyama-Abe; T Minaguchi; Y Nakamura; H Michikami; A Shikama; S Nakao; M Sakurai; H Ochi; M Onuki; K Matsumoto; T Satoh; A Oki; H Yoshikawa
Journal:  Br J Cancer       Date:  2013-08-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.